Psoriasis susceptibility genes LCE3D and TNIP1 and uses thereof

A technology for psoriasis and its application, which is applied in the field of psoriasis susceptibility genes LCE3D and TNIP1 and the preparation of detection kits, so as to avoid economic burden and drug side effects and improve clinical curative effect

Active Publication Date: 2019-02-01
AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Studies have found that gene polymorphisms of enzymes related to folic acid metabolism pathways are associated with the clinical efficacy and side effects of MTX in the treatment of rheumatoid arthritis: such as MTHFR1298A>C (rs1801131), ATIC347C>G (rs2372536), RFC-180G> A(rs1051266), SLC19A1A>G(rs2838956) ...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Psoriasis susceptibility genes LCE3D and TNIP1 and uses thereof
  • Psoriasis susceptibility genes LCE3D and TNIP1 and uses thereof
  • Psoriasis susceptibility genes LCE3D and TNIP1 and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Example 1: Observation of clinical efficacy and side effects of MTX intervention in the treatment of psoriasis

[0023] Materials and Methods:

[0024] 1) Patients with psoriasis: Patients with psoriasis who visited the Psoriasis Clinic of the Department of Dermatology of Huashan Hospital from January 2015 to June 2017 were selected as observation objects.

[0025] 2) Medication intervention method: oral administration of MTX7.5mg once a week in the 1st and 2nd week of treatment, 10mg a single oral administration a week from the 3rd to 4th week, and 12.5mg a single oral administration a week from the 5th to 12th week.

[0026] 3) Inclusion criteria

[0027] (1) Age 18-60;

[0028] (2) Patients diagnosed with vulgaris, arthropathic, erythrodermic and pustular psoriasis, body surface area involved (BSA)>10% or psoriasis area and severity index (PASI)> 10;

[0029] (3) Fill out the complete epidemiological survey form and sign the informed consent form.

[0030] 4) Ex...

Embodiment 2

[0041] Example 2 Correlation between psoriasis susceptibility genes and MTX clinical efficacy

[0042] Materials and methods: DNA was extracted from patients, and 18 non-HLA loci of 90 patients were genotyped using the sequenom platform. The effective group and the ineffective group were defined according to whether PASI75 reached 12w or not. Bioinformatics analysis showed that, The LCE3D genotype was statistically significant between the effective group and the ineffective group;

[0043] (1) Comparison of patient information between the effective group and the ineffective group of MTX treatment

[0044] Treated with MTX for 12 weeks to achieve PASI75 improvement as the effective group, and the rest as the ineffective group, the disease duration of the effective group (19±12) was significantly longer than that of the ineffective group (14±11), the difference was statistically significant p<0.05; LCE3DSNP locus rs4112788AG The probability of genotype is significantly higher t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of biotechnology, relates to psoriasis susceptibility genes and uses thereof, and particularly relates to psoriasis susceptibility genes LCE3D and TNIP1 and use thereof in preparing a detection kit. The invention provides new gene markers especially LCE3D SNP locus rs4112788AG genotype and TNIP1 SNP locus rs10036748TT genotype for predicting MTX clinical treatment effect, the new gene markers can be used as gene markers for predicting the clinical efficacy and toxic side effects of MTX intervention in the treatment of psoriasis; the invention also provides the detection kit. The kit predicts the clinical efficacy and side effects of MTX by detecting SNP loci in the psoriasis susceptibility genes LCE3D and TNIP1. The kit can be further used to predict theclinical efficacy and side effects of the MTX in the treatment of the psoriasis, and helps clinicians to develop appropriate MTX treatment intervention schedules.

Description

technical field [0001] The invention belongs to the field of biotechnology, and relates to psoriasis susceptibility genes and applications thereof, in particular to psoriasis susceptibility genes LCE3D and TNIP1 and their application in the preparation of a detection kit, which detects the susceptibility of psoriasis patients The SNP sites of the sensitive genes LCE3D and TNIP1 predict the clinical efficacy and side effects of MTX. Background technique [0002] The prior art discloses that psoriasis is a common chronic inflammatory disease that can affect multiple organs such as the skin, nails, joints, kidneys, and cardiovascular system; It brings serious physical and mental damage and economic burden to patients. Among the drug interventions commonly used in clinical practice, the effective rate of commonly used acitretin is only about 20%, and it will cause increased blood lipids, increase the risk of cardiovascular disease in patients, and some patients will also suffer...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12Q1/6883
CPCC12Q1/6883C12Q2600/106C12Q2600/172C12Q2600/156
Inventor 颜克香徐金华张学军
Owner AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap